Similarly, several previous studies have shown that MCTS1 expression may be a potential prognostic indicator of reduced survival in patients with certain solid tumors, including lung cancer, oral cancer, bladder cancer, malignant pleural mesothelioma, gastrointestinal stromal tumors, clear cell renal cell carcinoma, and breast cancer subtypes Luminal A and B (Huang et al., 2021; Gao et al., 2021; Tian et al., 2020; Kim et al., 2015; de Oliveira et al., 2012; Choi et al., 2014; Dell’Anno et al., 2020). Here, MCTS1 is linked to breast carcinoma.